Short answer
Protalix BioTherapeutics, Inc. (PLX) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $22M (up 22.8% year over year) with net income of $4M.
Q3 2026 key financials · XBRL
- Revenue
- $22M
- +22.8% YoY · +10.2% QoQ
- Net income
- $4M
- +68.2% YoY · +4.9% QoQ
- Operating margin
- 18.5%
- EPS (diluted)
- $0.04
- +33.3% YoY · −20.0% QoQ
Source: XBRL data from the Protalix BioTherapeutics, Inc. (PLX) Q3 2026 10-Q on SEC EDGAR. USD.
Protalix BioTherapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $21.925M, up from $17.851M YoY, driven by selling-goods revenue of $21.834M
- Q3 operating margin 18.5% vs 11.9% YoY, with operating income $4.047M vs $2.131M
- Best segment Chiesi, Q3 sales $13.138M vs $8.763M; worst Fiocruz, $4.365M vs $6.105M
- Cash and short-term deposits $48.5M; nine-month operating cash flow $15.529M vs $(14.023)M YoY
- Management expects rising R&D spending for the RELEASE study, with funds sufficient for at least 12 months
Risk Factors
- No material changes to previously disclosed risk factors in the 2025 Form 10-K
- No material changes to risk factors reported in the June 30, 2026 Form 10-Q
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protalix BioTherapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.